Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

672
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
672
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

521
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
521
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

470
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: The key role of Mer receptor tyrosine kinase: where inflammation ends and fibrosis begins.

Frontiers in immunology·2023
Same author

Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?

The Lancet. Rheumatology·2020
Same author

Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sjögren's model.

Journal of autoimmunity·2020
Same author

Proteins in assemblages formed by phase separation possess properties that promote their transformation to autoantigens: Implications for autoimmunity.

Journal of autoimmunity·2020
Same author

Gas6/TAM Receptors in Systemic Lupus Erythematosus.

Disease markers·2019
Same author

Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.

Inflammation·2018

Related Experiment Video

Updated: Sep 11, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.0K

Can we cure lupus?

Tessa L Clement1, Philip L Cohen1

  • 1Section of Rheumatology, Lewis Katz School of Medicine at Temple University, 3322 North Broad Street, Suite 201, Philadelphia, PA 19410, USA.

Current Opinion in Immunology
|August 16, 2025
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for treating systemic lupus erythematosus, offering potential long-term remission. Advances in T-cell and NK cell therapies may provide new, practical treatments for this autoimmune disease.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.9K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

220

Related Experiment Videos

Last Updated: Sep 11, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.0K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.9K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

220

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Cellular Therapy

Background:

  • Systemic lupus erythematosus (SLE) pathogenesis is increasingly understood, but current treatments remain largely empirical and often unsatisfactory.
  • Previous targeted therapies, including monoclonal antibodies and stem cell treatments, have shown limited success in managing SLE.
  • Refractory SLE cases have seen unexpected promise with chimeric antigen receptor T-cell (CAR-T) therapy directed against B cells.

Purpose of the Study:

  • To review the emerging potential of CAR-T cell therapy in treating systemic lupus erythematosus.
  • To discuss the implications of recent advancements in cellular therapies for SLE management.
  • To highlight the role of systems biology and single-cell approaches in uncovering new therapeutic targets for SLE.

Main Methods:

  • Review of recent clinical findings and research in cellular therapy for systemic lupus erythematosus.
  • Analysis of the efficacy of CAR-T cell therapy in small patient cohorts with refractory disease.
  • Exploration of systems biology and single-cell technologies for understanding SLE pathogenesis.

Main Results:

  • CAR-T cell therapy has demonstrated unexpected promise in small patient series, leading to apparent long-term and complete remission of SLE.
  • Progress in T-cell and natural killer (NK) cell therapies suggests more accessible and practical treatment methods are on the horizon.
  • Advancements in understanding SLE mechanisms are identifying novel pathways for therapeutic intervention.

Conclusions:

  • CAR-T cell therapy represents a significant advancement in treating refractory systemic lupus erythematosus.
  • Future developments in cellular immunotherapies, including T-cell and NK cell-based strategies, hold great potential for SLE patients.
  • Continued research into SLE pathogenesis using systems biology and single-cell analysis will likely yield new therapeutic options, potentially leading to long-term disease control or cure.